InBody (041830) Fundamentals 2026 — P/E 16.0x, Revenue Analysis | SniperIQ
InBody (041830) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩663.1B, trading at ₩49700.00 on the KOE. This SniperIQ fundamentals page covers InBody's valuation (P/E 16.0x, P/B 2.0x), profitability (net margin 16.2%), revenue (₩233.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is InBody's market cap?
InBody (041830) has a market capitalization of approximately ₩663.1B, trading at ₩49700.00 on the KOE. Market cap moves with the live share price.
What is InBody's P/E ratio?
InBody's trailing twelve-month P/E ratio is 16.0x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is InBody?
InBody runs a net profit margin of 16.2%, a gross margin of 75.5%, and an operating margin of 17.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does InBody generate?
InBody reported revenue of ₩233.9B for fiscal year 2025, with net income of ₩30.6B and earnings per share (EPS) of 2423. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does InBody pay a dividend?
InBody offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is InBody financially healthy?
InBody carries a debt-to-equity ratio of 0.03x and a current ratio of 5.30x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is InBody a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For InBody (041830) the key facts are: market cap ₩663.1B, P/E 16.0x, revenue ₩233.9B, 52-week range 23100-64200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track InBody's full fundamentals live
Get InBody's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.